Joy Fisher

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07
    Tracy Batchelor
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 21:1044-9. 2003
  2. pmc A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)
    L Burt Nabors
    Brain Tumor Treatment and Research Program, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Cancer 118:5601-7. 2012
  3. ncbi request reprint Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials
    Kathryn A Carson
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 25:2601-6. 2007
  4. pmc Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study
    John J Laterra
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Neuro Oncol 6:15-20. 2004
  5. ncbi request reprint An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial
    Stephen B Tatter
    Department of Neurosurgery, Wake Forest University, Winston Salem, North Carolina, USA
    J Neurosurg 99:297-303. 2003
  6. ncbi request reprint Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial
    Alessandro Olivi
    The New Approaches to Brain Tumor Therapy CNS Consortium, 1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 21:1845-9. 2003
  7. pmc Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 16:2443-9. 2010
  8. pmc Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 27:4155-61. 2009
  9. doi request reprint The analgesic effect of magnetic acupressure in cancer patients undergoing bone marrow aspiration and biopsy: a randomized, blinded, controlled trial
    Ting Bao
    The University of Maryland Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21212, USA
    J Pain Symptom Manage 41:995-1002. 2011
  10. pmc Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma
    Surasak Phuphanich
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuro Oncol 10:617-23. 2008

Detail Information

Publications18

  1. ncbi request reprint Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07
    Tracy Batchelor
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 21:1044-9. 2003
    ..A multicenter, phase II study of single-agent, intravenous methotrexate in newly diagnosed non-AIDS-related primary CNS lymphoma was conducted in the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium...
  2. pmc A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)
    L Burt Nabors
    Brain Tumor Treatment and Research Program, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Cancer 118:5601-7. 2012
    ....
  3. ncbi request reprint Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials
    Kathryn A Carson
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 25:2601-6. 2007
    ..Prognostic factor analyses have proven useful in predicting outcome in patients with newly diagnosed malignant glioma. Similar analyses in patients with recurrent glioma could affect the design and conduct of clinical trials substantially...
  4. pmc Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study
    John J Laterra
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Neuro Oncol 6:15-20. 2004
    ..However, overall survival is not significantly improved when compared with the New Approaches to Brain Tumor Therapy GBM database or other comparable patient populations...
  5. ncbi request reprint An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial
    Stephen B Tatter
    Department of Neurosurgery, Wake Forest University, Winston Salem, North Carolina, USA
    J Neurosurg 99:297-303. 2003
    ..In this study the authors evaluated the safety and performance of the GliaSite Radiation Therapy System (RTS) in patients with recurrent malignant brain tumors who were undergoing tumor resection...
  6. ncbi request reprint Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial
    Alessandro Olivi
    The New Approaches to Brain Tumor Therapy CNS Consortium, 1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 21:1845-9. 2003
    ....
  7. pmc Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 16:2443-9. 2010
    ..Results of these phase II studies are typically compared with the phase III European Organization for Research and Treatment of Cancer (EORTC) survival data that resulted in RT + TMZ becoming standard therapy...
  8. pmc Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 27:4155-61. 2009
    ..Talampanel is a well-tolerated, oral alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor blocker that could be beneficial in this disease...
  9. doi request reprint The analgesic effect of magnetic acupressure in cancer patients undergoing bone marrow aspiration and biopsy: a randomized, blinded, controlled trial
    Ting Bao
    The University of Maryland Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21212, USA
    J Pain Symptom Manage 41:995-1002. 2011
    ..Bone marrow aspiration and biopsy (BMAB) is a frequently performed and painful procedure...
  10. pmc Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma
    Surasak Phuphanich
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuro Oncol 10:617-23. 2008
    ..Further study of atrasentan with radiation therapy and temozolomide in newly diagnosed GBM is warranted to evaluate the efficacy of this novel agent...
  11. ncbi request reprint Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
    L Burt Nabors
    New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231, USA
    J Clin Oncol 25:1651-7. 2007
    ..This multi-institutional phase I trial was designed to determine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perfusion magnetic resonance imaging (MRI) in patients with recurrent malignant glioma...
  12. pmc Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial
    Jon Weingart
    New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD, USA
    J Clin Oncol 25:399-404. 2007
    ....
  13. ncbi request reprint Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma
    Mark R Gilbert
    Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 9:2940-9. 2003
    ....
  14. ncbi request reprint The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride
    Stuart A Grossman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Massachusetts General Hospital, Boston, USA
    Clin Cancer Res 12:5174-81. 2006
    ..This study was conducted to determine if the maximum tolerated dose and pharmacokinetics of PCB are affected by the concurrent use of enzyme-inducing antiseizure drugs (EIASD)...
  15. pmc Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma
    Steven Brem
    Department of Interdisciplinary Oncology and Neurosurgery, University of South Florida College of Medicine and Neuro Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL 33620, USA
    Neuro Oncol 7:246-53. 2005
    ..Although serum copper was effectively reduced by diet and penicillamine, this antiangiogenesis strategy did not improve survival in patients with glioblastoma multiforme...
  16. pmc Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study
    Surasak Phuphanich
    The New Approaches to Brain Tumor Therapy CNS Consortium, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Neuro Oncol 7:177-82. 2005
    ..The pharmacology of PB appears to be affected by concomitant administration of P450-inducing anticonvulsants...
  17. ncbi request reprint A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting
    E Antonio Chiocca
    The NABTT CNS Consortium, Baltimore, MD 21231, USA
    Mol Ther 10:958-66. 2004
    ..In 2 patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed. Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 10(10) pfu...
  18. ncbi request reprint Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme
    Tom Mikkelsen
    Department of Neurology, Henry Ford Health System, Detroit, Michigan 48202, USA
    Invest New Drugs 25:259-63. 2007
    ..This study examined the efficacy, safety and pharmacokinetics of oral CAI in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM) in an open-label, single arm non-randomized phase 2 trial...